Ona Therapeutics (“Ona”), a global biotech company pioneering first-in-class antibody-drug conjugates (ADCs), today announced key leadership appointments to support its rapid growth and pipeline advancement. Dr. Aleix Prat, a global leader in drug and biomarker development, has been appointed Chair of the Advisory Board. Additionally,
Dr. Jutta Amersdorffer has joined as Chief Medical Officer and Stéphane Durant des Aulnois as Chief Financial Officer. 

Read more